Delcath Systems, Inc. to Present Poster at International Liver Cancer Association 2009 Annual Conference
04 September 2009 - 1:00PM
PR Newswire (US)
NEW YORK, Sept. 4 /PRNewswire-FirstCall/ -- Delcath Systems, Inc.
(NASDAQ: DCTH), a medical technology company testing its
proprietary treatment method for primary and metastatic cancers to
the liver, announced that Dr. James F. Pingpank, Associate
Professor of Surgery for the University of Pittsburgh School of
Medicine will present an abstract at the International Liver Cancer
Association's (ILCA) Third Annual Conference on Saturday, September
5, 2009 in Milan, Italy. Dr. Pingpank's poster is titled,
"Percutaneous hepatic perfusion (PHP) with melphalan for patients
with unresectable hepatic metastases from ocular and cutaneous
melanomas." Eamonn Hobbs, President and CEO of Delcath Systems
stated, "ILCA is an excellent forum for Delcath to increase the
medical communities' awareness of the Delcath PHP System(TM) as we
move towards full enrollment of our pivotal Phase III study. Our
presence is important as we prepare for commercialization and
introduce our PHP System(TM) to European physicians, surgeons and
medical oncologists. Participation also allows us further insight
into current marketing and selling initiatives abroad." About the
Phase III Study This clinical study is testing the Delcath PHP
System(TM) for the regional delivery of melphalan to the liver to
treat patients with metastatic cutaneous and ocular melanoma who
have unresectable tumors in the liver. The Delcath PHP System(TM)
is designed to deliver significantly higher doses of anti-cancer
drugs to a patient's liver while minimizing entry of the drugs into
the rest of the patient's circulation. This isolation limits
toxicities which result from systemic chemotherapy treatments.
Patients in the Phase III trial are randomized into one of two
treatment arms, including immediate treatment with melphalan via
the Delcath PHP System(TM) or treatment with best alternative care.
The study is designed to evaluate the duration of tumor response in
each of the two study arms. Following guidelines established by
U.S. Food and Drug Administration under a Special Protocol
Assessment (SPA), patients are permitted to "cross-over" from the
best alternative care arm to receive treatment with the Delcath
System at the time of disease progression. About Delcath Systems,
Inc. Delcath Systems, Inc. is a medical device company specializing
in cancer treatment. The Company is testing a proprietary, patented
drug delivery system for the treatment of liver cancers. Delcath's
novel drug delivery platform is testing the delivery of ultra-high
doses of anti-cancer drugs to the liver while preventing these high
doses of drug from entering the patient's bloodstream. The Company
is currently enrolling patients in Phase III and Phase II clinical
studies for the treatment of liver cancers using high doses of
melphalan. The Company's intellectual property portfolio consists
of twenty-seven patents on a worldwide basis including the U.S.,
Europe, Asia and Canada. For more information, please visit the
Company's website at http://www.delcath.com/. DATASOURCE: Delcath
Systems, Inc. CONTACT: Investors, Doug Sherk, Stacey Fisher, or
Mike Pollack, +1-415-896-6820, or Media, Steve DiMattia,
+1-646-201-5445, all of EVC Group, for Delcath Systems, Inc. Web
Site: http://www.delcath.com/
Copyright